← Back to headlines
Regeneron Anticipates $102 Million in Q1 Pre-Tax IPR&D Charges
Biotechnology company Regeneron Pharmaceuticals expects to incur approximately $102 million in pre-tax in-process research and development charges for the first quarter.
8 Apr, 11:32 — 8 Apr, 11:32
Sources
Showing 1 of 1 sources
